The price of Timber Pharmaceuticals Inc. (AMEX:TMBR) shares last traded on Wall Street rose 2.31% to $2.21.
Based on available information, 1 analysts follow Timber Pharmaceuticals Inc. (AMEX:TMBR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $50.00 and a low of $50.00, we find $50.00. Given the previous closing price of $2.16, this indicates a potential upside of 2214.81 percent. TMBR stock price is now 33.48% away from the 50-day moving average and -73.21% away from the 200-day moving average. The market capitalization of the company currently stands at $5.77M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 0 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $50.00 as their price target over the next twelve months.
.
Insiders disposed of 19,630 shares of company stock worth roughly $43382.3 over the past 1 year. A total of 0.28% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TMBR stock. A new stake in Timber Pharmaceuticals Inc. shares was purchased by SUSQUEHANNA INTERNATIONAL GROUP, LLP during the first quarter worth $14,000. BANK OF NEW YORK MELLON CORP invested $13,000 in shares of TMBR during the first quarter. In the first quarter, VICTORY CAPITAL MANAGEMENT INC acquired a new stake in Timber Pharmaceuticals Inc. valued at approximately $1,000. In total, there are 16 active investors with 4.30% ownership of the company’s stock.
A candlestick chart of Timber Pharmaceuticals Inc. (AMEX: TMBR) showed a price of $2.3000 on Tuesday morning. During the past 12 months, Timber Pharmaceuticals Inc. has had a low of $1.20 and a high of $20.52. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.40, and a quick ratio of 2.40. The fifty day moving average price for TMBR is $1.6557 and a two-hundred day moving average price translates $7.8454 for the stock.
The latest earnings results from Timber Pharmaceuticals Inc. (AMEX: TMBR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.15, missing analysts’ expectations of -$0.04 by -0.11. This compares to -$4.10 EPS in the same period last year. For the current quarter, analysts expect TMBR to generate $150k in revenue.
Timber Pharmaceuticals Inc.(TMBR) Company Profile
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company’s lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
